Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lenz Therapeutics Q3 2026 Results: Net Loss of $31M, Loss Widens

LENZ Therapeutics transitioned to a commercial-stage company following the FDA approval of VIZZ in July 2025, reporting its first product sales of $6.0 million for the nine months ended September 30, 2026. Despite the new revenue stream, the company saw a significant increase in net loss to $104.4 million for the same period, driven primarily by a surge in selling, general, and administrative expenses to $120.2 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue3.412.5
Profit before tax-31.0-16.7
Net income-31.0-16.7
EPS (diluted, $ a share)$-0.99$-0.59

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-72.9%
Source

10-Q filed with the SEC, NASDAQ: LENZ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lenz Therapeutics, Inc.: key numbers

Share price
$3.50Close, Nov 17
Market cap
$110M
Shares outstanding
31.42MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lenz Therapeutics, Inc.

All →
5:44 PM ET Form 4
Insider Selling

Lenz Therapeutics 10% Owner Ra Capital Management L.P. Sells $9.13M of Stock

Ra Capital Management L.P., 10% Owner, sold 2,718,684 shares of Lenz Therapeutics, Inc. at $3.36 a share, worth $9.13M in total on Oct 29, 2026. Shares held after the trade: 57,559 (-65.1%).

Value
$9.13M
Shares
2,718,684
Average price
$3.36
Role
10% Owner
Holding change
-65.1%
Trade date
Oct 29, 2026
4:35 PM ET 8-K
Financial Results

Lenz Therapeutics Financial Results

LENZ Therapeutics reported Q3 2026 financial results featuring a 50% sequential increase in VIZZ product sales. Alongside results, the company announced a strategic reorganization reducing headcount by 75% to focus on consumer marketing and a leadership transition where CEO Eef Schimmelpennink will be succeeded by CFO Dan Chevallard as Interim CEO on December 1, 2026.

Term
Q3 2026

“Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates. We view these as promising indicators of our positive trajectory in this emerging market.”

Eef Schimmelpennink, President and Chief Executive Officer

“After nearly six years leading LENZ and more than 25 years in the biotechnology industry, I have decided to transition from my role as CEO effective December 1, 2026, to devote more time to other passions.”

Eef Schimmelpennink, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.